<DOC>
	<DOCNO>NCT00000991</DOCNO>
	<brief_summary>To evaluate compare 3 anti-pneumocystis regimen plus zidovudine ( AZT ) person HIV infection T4 cell count le 200 cells/mm3 . All person complete least 8 week therapy 081 offer opportunity participate nest study ( ACTG 981 ) systemic antifungal therapy ( fluconazole ) versus local therapy ( Clotrimazole ) prevention serious fungal disease . Persons HIV disease receive AZT risk PCP , toxoplasmosis , bacterial pneumonia , serious infection . It therefore important find drug give along AZT control infection . Aerosolized pentamidine ( PEN ) show useful prevent PCP expect low 2-year risk PCP . Both sulfamethoxazole/trimethoprim ( SMX/TMP ) dapsone probably also provide effective preventive treatment PCP , may useful prevent toxoplasmosis extrapulmonary pneumocystosis .</brief_summary>
	<brief_title>A Study Three Drugs Plus Zidovudine Prevention Infections HIV-Infected Patients</brief_title>
	<detailed_description>Persons HIV disease receive AZT risk PCP , toxoplasmosis , bacterial pneumonia , serious infection . It therefore important find drug give along AZT control infection . Aerosolized pentamidine ( PEN ) show useful prevent PCP expect low 2-year risk PCP . Both sulfamethoxazole/trimethoprim ( SMX/TMP ) dapsone probably also provide effective preventive treatment PCP , may useful prevent toxoplasmosis extrapulmonary pneumocystosis . All patient receive AZT . In addition , place one three group receive either SMX/TMP , dapsone , PEN . Stratification criterion : Received first AZT equal less 6 week prior study entry . Received first AZT 6 week prior study entry . Potential participate ACTG 981 . ACTG center patient enrol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antifolate medication require treat intercurrent infection . Treatment intercurrent infection malignancy . Fluconazole . Itraconazole . Standard investigational therapy pneumocystosis ( PCP ) toxoplasmosis . Only form primary prophylaxis PCP toxoplasmosis assign participant protocol . Patients develop intolerance form prophylaxis assign protocol develop PCP toxoplasmosis may receive alternate investigation form prophylaxis without zidovudine must continue follow protocol . Discouraged allow : AL721 . Chronic acyclovir . Ketoconazole . Amphotericin B. Corticosteroids great physiologic replacement dose strongly discourage . They use briefly possible definite specific indication . Patient must conform following : Receiving candidate zidovudine therapy least 500 mg/day current label indication history pneumocystosis ( PCP ) toxoplasmosis . Evidence HIV infection document HIV antibody test . T4 cell count le 200 cells/mm3 time prior study entry . Willing sign inform consent . Willing follow participate ACTG center duration study . Allowed : Concurrent enrollment longterm followup study previously blind trial AZT ( ACTG 016 019 ) . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : History document presumed pneumocystosis ( PCP ) toxoplasmosis . Active bacterial mycobacterial infection . History type I hypersensitivity , exfoliative rash , rash mucosal involvement , severe bronchospasm , lifethreatening reaction study drug sulfas , sulfones , pentamidine . History intolerance cause dose interruption receive zidovudine equal less 600 mg/day cause dose reduction le 500 mg/day within 4 week prior entry . Advanced Kaposi 's sarcoma malignancy specifically allow rapidly progressive month prior enrollment may expect require chemotherapy within 90 day study entry . Concurrent Medication : Excluded : Active primary treatment infection malignancy . Other form antifolate medication specifically allow . Other antiretroviral biologic response modifier . Ganciclovir , cause intolerance AZT equal 500 mg/day . Foscarnet . Patients follow exclude : Symptoms condition define Exclusion Coexisting Conditions . Glucose 6phosphate dehydrogenase deficiency ( GPD ) . History pneumocystosis ( PCP ) toxoplasmosis . History type I hypersensitivity , exfoliative rash , rash mucosal involvement , severe bronchospasm , lifethreatening reaction study drug sulfas , sulfones , pentamidine . History intolerance cause dose interruption receive zidovudine equal less 500 mg/day 4 week pior study entry . Prior Medication : Excluded within 4 week study entry : Any form pneumocystosis ( PCP ) chemoprophylaxis . Active substance abuse , include alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Toxoplasmosis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Dapsone</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>